AdvisorNet Financial Inc Grows Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

AdvisorNet Financial Inc increased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNGet Rating) by 104.3% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 239 shares of the biopharmaceutical company’s stock after purchasing an additional 122 shares during the quarter. AdvisorNet Financial Inc’s holdings in Regeneron Pharmaceuticals were worth $141,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Bailard Inc. purchased a new position in shares of Regeneron Pharmaceuticals in the 1st quarter valued at approximately $210,000. Kovitz Investment Group Partners LLC bought a new position in Regeneron Pharmaceuticals during the 1st quarter valued at approximately $2,065,000. Steward Partners Investment Advisory LLC increased its position in Regeneron Pharmaceuticals by 1.4% during the 1st quarter. Steward Partners Investment Advisory LLC now owns 3,756 shares of the biopharmaceutical company’s stock valued at $2,623,000 after buying an additional 53 shares in the last quarter. B. Metzler seel. Sohn & Co. AG increased its position in Regeneron Pharmaceuticals by 14.8% during the 1st quarter. B. Metzler seel. Sohn & Co. AG now owns 7,513 shares of the biopharmaceutical company’s stock valued at $5,248,000 after buying an additional 968 shares in the last quarter. Finally, Achmea Investment Management B.V. bought a new position in Regeneron Pharmaceuticals during the 1st quarter valued at approximately $17,405,000. Hedge funds and other institutional investors own 84.92% of the company’s stock.

Insider Activity

In other news, Director Arthur F. Ryan sold 10,453 shares of the business’s stock in a transaction dated Thursday, August 4th. The stock was sold at an average price of $621.29, for a total value of $6,494,344.37. Following the transaction, the director now directly owns 18,408 shares in the company, valued at $11,436,706.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other news, Director Arthur F. Ryan sold 10,453 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, August 4th. The stock was sold at an average price of $621.29, for a total value of $6,494,344.37. Following the sale, the director now directly owns 18,408 shares of the company’s stock, valued at $11,436,706.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Marion Mccourt sold 1,100 shares of Regeneron Pharmaceuticals stock in a transaction dated Friday, July 1st. The stock was sold at an average price of $587.76, for a total value of $646,536.00. Following the completion of the sale, the executive vice president now directly owns 19,644 shares in the company, valued at $11,545,957.44. The disclosure for this sale can be found here. Insiders have sold 56,740 shares of company stock worth $35,478,694 over the last ninety days. Corporate insiders own 8.99% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN opened at $684.63 on Thursday. The company has a market capitalization of $74.63 billion, a PE ratio of 13.67, a price-to-earnings-growth ratio of 2.47 and a beta of 0.29. The company has a debt-to-equity ratio of 0.13, a quick ratio of 4.39 and a current ratio of 5.12. The business’s fifty day moving average is $623.33 and its 200 day moving average is $640.95. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $538.01 and a fifty-two week high of $754.67.

Regeneron Pharmaceuticals (NASDAQ:REGNGet Rating) last released its earnings results on Wednesday, August 3rd. The biopharmaceutical company reported $9.77 earnings per share for the quarter, missing the consensus estimate of $9.94 by ($0.17). Regeneron Pharmaceuticals had a net margin of 39.97% and a return on equity of 36.17%. The company had revenue of $2.86 billion for the quarter, compared to analysts’ expectations of $2.80 billion. During the same quarter last year, the firm posted $27.97 earnings per share. Regeneron Pharmaceuticals’s revenue for the quarter was down 44.4% on a year-over-year basis. Sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 36.16 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on REGN shares. Canaccord Genuity Group raised their price objective on Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the company a “buy” rating in a research report on Friday, September 16th. StockNews.com lowered Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, July 26th. Guggenheim lifted their target price on Regeneron Pharmaceuticals from $740.00 to $925.00 in a report on Monday, September 12th. Cantor Fitzgerald initiated coverage on Regeneron Pharmaceuticals in a report on Tuesday, July 12th. They issued a “neutral” rating and a $625.00 target price for the company. Finally, Wells Fargo & Company lifted their target price on Regeneron Pharmaceuticals from $735.00 to $800.00 and gave the stock an “overweight” rating in a report on Monday, September 12th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and thirteen have given a buy rating to the company. According to MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $746.33.

About Regeneron Pharmaceuticals

(Get Rating)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Further Reading

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNGet Rating).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.